BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...including the acquisition of single-asset menopause company Kandy...
BioCentury | Feb 19, 2021
Product Development

Phase III Astellas readout marks step forward for non-hormonal menopause therapies

...last year gained a late-stage dual NKR1/NKR3 antagonist to treat menopause symptoms via its takeout of KaNDy Therapeutics...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

...15-year period.” Advent’s biggest recent exit was the Bayer AG (Xetra:BAY) acquisition of women’s health company KaNDy Therapeutics Ltd....
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...a flourish, a $425 million takeout of KaNDy Therapeutics Ltd....
BioCentury | Dec 28, 2020
Deals

Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back

...half. In August, Bayer AG (Xetra:BAYN) acquired KaNDy Therapeutics Ltd....
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...the August acquisition of women’s health play KaNDy Therapeutics Ltd....
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...KaNDy Therapeutics Ltd., which was developing a program from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Bayer AG (Xetra:BAYN) bought KaNDy...
BioCentury | Sep 24, 2020
Finance

Data Bytes: record fund for Longitude follows rush of deals, IPOs

...Roche (SIX:ROG; OTCQX:RHHBY), announced on Sept. 21, and the August acquisition of women’s health play KaNDy Therapeutics Ltd....
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...Acquisition tops Bayer’s KaNDy buy as Europe’s largest this year By stephen hansen, associate editor With...
...topping the $425 million Bayer AG (Xetra:BAY) paid for another Forbion portfolio company, women’s health play KaNDy Therapeutics Ltd....
BioCentury | Aug 18, 2020
Product Development

I Want KaNDy, plus Sputnik V & M&A amid COVID-19: a BioCentury podcast

...By BC Staff Bayer’s deal with KaNDy could be a sign that companies are finally paying...
...dealmaking trends in biopharma.  Editor in Chief Simone Fishburn analyzes the dynamics behind the optimism of KaNDy Therapeutics Ltd....
...Women’s health (see “Single-Asset KaNDy Finds $425M Exit”).Jeff Cranmer, executive editor, notes that Bayer believes KaNDy’s...
Items per page:
1 - 10 of 16
BioCentury | Mar 6, 2021
Deals

How Bayer is building a cell and gene therapy business through deals

...including the acquisition of single-asset menopause company Kandy...
BioCentury | Feb 19, 2021
Product Development

Phase III Astellas readout marks step forward for non-hormonal menopause therapies

...last year gained a late-stage dual NKR1/NKR3 antagonist to treat menopause symptoms via its takeout of KaNDy Therapeutics...
BioCentury | Feb 18, 2021
Finance

Advent raises next funds, taps Midwest innovation

...15-year period.” Advent’s biggest recent exit was the Bayer AG (Xetra:BAY) acquisition of women’s health company KaNDy Therapeutics Ltd....
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...a flourish, a $425 million takeout of KaNDy Therapeutics Ltd....
BioCentury | Dec 28, 2020
Deals

Myovant’s deal with Pfizer for $650M up front is the latest sign women’s health is back

...half. In August, Bayer AG (Xetra:BAYN) acquired KaNDy Therapeutics Ltd....
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...the August acquisition of women’s health play KaNDy Therapeutics Ltd....
BioCentury | Oct 12, 2020
Finance

Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting

...KaNDy Therapeutics Ltd., which was developing a program from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Bayer AG (Xetra:BAYN) bought KaNDy...
BioCentury | Sep 24, 2020
Finance

Data Bytes: record fund for Longitude follows rush of deals, IPOs

...Roche (SIX:ROG; OTCQX:RHHBY), announced on Sept. 21, and the August acquisition of women’s health play KaNDy Therapeutics Ltd....
BioCentury | Sep 22, 2020
Deals

Next up, NodThera? Roche’s €380M deal for Inflazome is latest NLRP3 takeout

...Acquisition tops Bayer’s KaNDy buy as Europe’s largest this year By stephen hansen, associate editor With...
...topping the $425 million Bayer AG (Xetra:BAY) paid for another Forbion portfolio company, women’s health play KaNDy Therapeutics Ltd....
BioCentury | Aug 18, 2020
Product Development

I Want KaNDy, plus Sputnik V & M&A amid COVID-19: a BioCentury podcast

...By BC Staff Bayer’s deal with KaNDy could be a sign that companies are finally paying...
...dealmaking trends in biopharma.  Editor in Chief Simone Fishburn analyzes the dynamics behind the optimism of KaNDy Therapeutics Ltd....
...Women’s health (see “Single-Asset KaNDy Finds $425M Exit”).Jeff Cranmer, executive editor, notes that Bayer believes KaNDy’s...
Items per page:
1 - 10 of 16